GlassScriptPhysician profile
Scott W Geiger
NPI 1477917227
$7,000.42
in general payments reported to CMS, 2019-2025
27 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.84 · 2021: $835 · 2022: $2,560 · 2023: $1,535 · 2024: $962 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,087.60 | 2020-2024 | Axonics, Bulkamid |
| Abbvie INC. | $873.74 | 2021-2025 | |
| Astellas Pharma US INC | $780.75 | 2021-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $507.96 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $322.90 | 2021-2025 | Axonics |
| Urogen Pharma, INC. | $191.21 | 2023-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $143.38 | 2021-2023 | Xiaflex, Aveed |
| Endo USA, INC. | $123.88 | 2024-2025 | Aveed, Xiaflex |
| Pfizer INC. | $116.87 | 2022-2023 | |
| Janssen Biotech, INC. | $103.01 | 2021-2025 | Erleada |
| Richard Wolf Medical Instruments Corp. | $98.78 | 2023 | |
| Merck Sharp & Dohme LLC | $81.83 | 2021-2023 | Keytruda, Lynparza |
| Coloplast Corp | $75.35 | 2022 | |
| Procept Biorobotics Corporation | $67.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $66.50 | 2022-2024 | Lynparza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $63.10 | 2021-2022 | |
| Karl Storz Endoscopy-America | $58.39 | 2022-2023 | N.A. |
| Saluda Medical Americas, INC. | $31.27 | 2025 | Evoke |
| Ferring Pharmaceuticals INC. | $31.08 | 2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $27.80 | 2025 | Provenge |
| Medtronic, INC. | $27.00 | 2025 | Interstim |
| Olympus America INC. | $24.05 | 2025 | Itind System |
| Myriad Genetic Laboratories, INC. | $23.65 | 2025 | Prolaris |
| Tolmar Pharmaceuticals, INC. | $22.94 | 2021 | |
| Convatec INC. | $19.63 | 2023 | |
| Myovant Sciences INC. | $15.90 | 2022 | |
| Laborie Medical Technologies Corp. | $14.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.